Table 4. Summary of unpublished OAC/PCI trials.
| Study | AUGUSTUS† | ENTRUST AF-PCI | |||||
|---|---|---|---|---|---|---|---|
| Ax + P + A | Ax + P + Placebo | W + P + A | W + P + Placebo | E + P | W + P | ||
| OAC | Apixaban | Edoxaban | |||||
| Number | 4,600 | 1,500 | |||||
| Dose of OAC | 2.5–5 mg BD | INR 2–3 | 30–60 mg OD | INR 2–3 | |||
| Notes | P for 6 months | 12 months | |||||
| Bleeding definition | ISTH | ISTH | |||||
W, Warfarin; P, P2Y12 inhibitor; A, Aspirin; Ax, Apixaban; E, Edoxaban; OAC, oral anticoagulation; INR, international normalised ratio; PCI, percutaneous coronary intervention; BD, twice a day; OD, once daily.